Literature DB >> 16837706

National surveillance and the epidemiology of human Q fever in the United States, 1978-2004.

Jennifer H McQuiston1, Robert C Holman, Candace L McCall, James E Childs, David L Swerdlow, Herbert A Thompson.   

Abstract

Although Q fever is considered enzootic in the United States, surveillance for human Q fever has been historically limited. From 1978 through 1999, 436 cases (average = 20 per year) of human Q fever were reported. After Q fever became nationally reportable in 1999, 255 human Q fever cases (average = 51 per year) were reported with illness onset during 2000 through 2004. The median age of cases was 51 years, and most cases were male (77%). The average annual incidence of Q fever was 0.28 cases per million persons, and was highest in persons 50-59 years of age (0.39 cases per million). State-specific incidence ranged from a high of 2.40 cases per million persons in Wyoming, to 0 cases in some states. Since Q fever became reportable, case reports have increased by more than 250%. Surveillance for Q fever is essential to establish the distribution and magnitude of disease and to complement U.S. bioterrorism preparedness activities.

Entities:  

Mesh:

Year:  2006        PMID: 16837706     DOI: 10.4269/ajtmh.2006.75.1.0750036

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Serologic detection of a rare case of Q fever in New York City having hepatic and unusual renal complications.

Authors:  C S Pavia; C McCalla
Journal:  Infection       Date:  2010-04-08       Impact factor: 3.553

2.  Both Major Histocompatibility Complex Class I (MHC-I) and MHC-II Molecules Are Required, while MHC-I Appears To Play a Critical Role in Host Defense against Primary Coxiella burnetii Infection.

Authors:  Laura Buttrum; Lindsey Ledbetter; Rama Cherla; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  Q fever in the United States: summary of case reports from two national surveillance systems, 2000-2012.

Authors:  F Scott Dahlgren; Jennifer H McQuiston; Robert F Massung; Alicia D Anderson
Journal:  Am J Trop Med Hyg       Date:  2014-11-17       Impact factor: 2.345

4.  Eosinophils Affect Antibody Isotype Switching and May Partially Contribute to Early Vaccine-Induced Immunity against Coxiella burnetii.

Authors:  Lindsey Ledbetter; Rama Cherla; Catherine Chambers; Yan Zhang; Guoquan Zhang
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

5.  Role of B cells in host defense against primary Coxiella burnetii infection.

Authors:  Laura Schoenlaub; Alexandra Elliott; Danielle Freches; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

Review 6.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Attenuated Coxiella burnetii phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection.

Authors:  Javier Ochoa-Repáraz; Jami Sentissi; Theresa Trunkle; Carol Riccardi; David W Pascual
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

8.  The devil is in the details.

Authors:  Ian Jenkins; Joseph Vinetz
Journal:  J Hosp Med       Date:  2009-07       Impact factor: 2.960

9.  Major Histocompatibility Complex Class II-Restricted, CD4+ T Cell-Dependent and -Independent Mechanisms Are Required for Vaccine-Induced Protective Immunity against Coxiella burnetii.

Authors:  Lindsey Ledbetter; Rama Cherla; Catherine Chambers; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

10.  Emergence of q Fever.

Authors:  E Angelakis; D Raoult
Journal:  Iran J Public Health       Date:  2011-09-30       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.